WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Thursday, August 4, 2016

Researchers Discover Why L-DOPA Stops Working in Parkinson's, Seek Prolonged Treatment

Magdalena KegelAug. 4, 2016


In a discovery that might turn out to be a game changer in Parkinson’s research, University of Alabama at Birmingham researchers discovered that DNA methylation causes L-DOPA to stop being effective after a few years, instead giving rise to dyskinesia — involuntary jerky movements making life even harder for patients.
In the study “Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia,published in the Journal of Neuroscience, the research team showed that increasing or lowering the methylation in animals impacts dyskinesia symptoms, potentially offering a treatment in the future.
When researchers discovered that L-DOPA could treat immobile people who had Parkinson’s disease, it was a significant breakthrough. Patients began moving and talking just like their old selves. But as every patient knows, this turned out to be short-lived. After a couple of years, instead of helping patients regain normal function, L-DOPA triggers gross involuntary movements. And once the condition sets it, there is no way forward unless L-DOPA is stopped.
This change that occurs has mystified researchers for decades. Scientists know that the side effects are a consequence of neurons becoming more sensitive to the drug by changing their gene activity, but a more precise explanation has been missing. Now, the research team in Birmingham seems to have found the reason.
They discovered that L-DOPA triggered widespread changes in DNA methylation. This process is a common way for cells to change their gene activity in response to environmental factors. When enzymes place the molecular tags — in the form of chemical methyl groups — on the DNA, the genes become either less or more active.
The team found that in some areas, methyl groups were lost, while other parts of the DNA became heavily methylated in nerve cells from striatum — the brain region holding the dying dopamine-producing cells.
The team also treated animals with a compound called RG-108, or with methionine supplementation, and saw that they could change the dyskinetic behavior of the animals. While these treatments are not suitable for humans, the experiments provide a proof-of-concept that by changing the methylation it is possible to harness the development of dyskinesia, and so, prolong the effectivity of L-DOPA.
“L-DOPA is a very valuable treatment for Parkinson’s, but in many patients, its use is limited by dyskinesia,” Dr. David Standaert, MD, PhD, senior author of the study and the John N. Whitaker professor and chair of the Department of Neurology at UAB, said in a news release. “Better means of preventing or reversing L-DOPA-induced dyskinesia could greatly extend the use of L-DOPA without inducing intolerable side effects.”
http://parkinsonsnewstoday.com/2016/08/04/researchers-discover-why-l-dopa-stop-working-parkinsons-seeking-prolonged-treatment/

No comments:

Post a Comment